Centre for Bone and Arthritis Research, The Sahlgrenska Academy, University of Gothenburg, Box 480, 405 30 Gothenburg, Sweden.
Arthritis Res Ther. 2011 Jun 20;13(3):R96. doi: 10.1186/ar3371.
Postmenopausal patients with rheumatoid arthritis (RA) are often treated with corticosteroids. Loss of estrogen, the inflammatory disease and exposure to corticosteroids all contribute to the development of osteoporosis. Therefore, our aim was to investigate if addition of the selective estrogen receptor modulator raloxifene, or estradiol, could prevent loss of bone mineral density in ovariectomized and dexamethasone treated mice with collagen-induced arthritis (CIA).
Female DBA/1-mice were ovariectomized or sham-operated, and CIA was induced. Treatment with dexamethasone (Dex) (125 μg/d), estradiol (E2) (1 μg/d) or raloxifene (Ral) (120 μg/day) alone, or the combination of Dex + E2 or Dex + Ral, was started after disease onset, and continued until termination of the experiments. Arthritic paws were collected for histology and one of the femoral bones was used for measurement of bone mineral density.
Dex-treatment alone protected against arthritis and joint destruction, but had no effect on osteoporosis in CIA. However, additional treatment with either Ral or E2 resulted in completely preserved bone mineral density.
Addition of raloxifene or estradiol to dexamethasone-treatment in experimental postmenopausal polyarthritis prevents generalized bone loss.
患有类风湿关节炎（RA）的绝经后患者常接受皮质类固醇治疗。雌激素丧失、炎症性疾病和皮质类固醇暴露都会导致骨质疏松症的发生。因此，我们的目的是研究选择性雌激素受体调节剂雷洛昔芬或雌二醇的添加是否可以预防去卵巢和地塞米松处理的胶原诱导性关节炎（CIA）小鼠的骨密度丢失。
雌性 DBA/1 小鼠被去卵巢或假手术，然后诱导 CIA。地塞米松（Dex）（125 μg/d）、雌二醇（E2）（1 μg/d）或雷洛昔芬（Ral）（120 μg/天）单独治疗，或 Dex+E2 或 Dex+Ral 的联合治疗，在疾病发作后开始，并持续到实验结束。收集关节炎爪子进行组织学检查，并用一根股骨测量骨密度。
单独的 Dex 治疗可预防关节炎和关节破坏，但对 CIA 中的骨质疏松症没有影响。然而，用雷洛昔芬或雌二醇进行额外的治疗可完全保留骨密度。
在实验性绝经后多关节炎的地塞米松治疗中添加雷洛昔芬或雌二醇可预防全身性骨丢失。
